Dipal has been Chief Executive Officer of Entrada Therapeutics (NASDAQ: TRDA) and a Member of the Board of Directors since joining Entrada in 2017 as its first full-time employee shortly after the Company was founded and funded with seed capital. He previously served as President and Chief Executive Officer from 2017 to 2024. With a passion for patient-focused drug development, Dipal believes that understanding the patient experience and perspective is critical to advancing impactful therapies. That’s why he and the Entrada team proudly partner with patient advocacy organizations to listen and learn from patients and ensure Entrada’s programs are informed by diverse community perspectives. Prior to joining Entrada, Dipal was the Chief Business Officer at Amicus Therapeutics (NASDAQ: FOLD) a global biotechnology company focused on rare diseases. He also held senior level positions at a healthcare private equity fund and Catalent. Earlier in his career, Dipal worked in Merrill Lynch's Investment Banking Group and held several roles at Eli Lilly and Company (NYSE: LLY). Dipal holds an MBA from The Wharton School of the University of Pennsylvania and a BA from Rutgers University. He serves on the Board of Directors of Azenta Life Sciences (NASDAQ: AZTA), a leading provider of life sciences solutions and āshibio, a privately held, clinical-stage biotechnology company. He is also a Fellow of the Aspen Institute and serves on the Board of Advisors of Life Science Cares Boston.